FDA approves next-gen MicroPort CRM pacemakers
18 May 2023
The cardiac rhythm management subsidiary of MicroPort Scientific said its newly approved devices are the longest-lasting pacemakers for their size on the market today. They offer a volume of just 11cc and a projected longevity of 13 years.
Additionally, the company also received approval for the associated Vega pacing leads, SmartTouch XT tablet-based programmer and SmartView Connect Bluetooth home monitor.
MicroPort CRM said it marks a “significant achievement” for patient care. It also demonstrates the Clamart, France-based company’s commitment to the U.S. market.
“MicroPort CRM has always been committed to providing medical devices with the most advanced technology and features to improve patient outcomes and reduce the burden on the healthcare system”, said Benoît Clinchamps, president of MicroPort CRM. “Alizea and Celea pacemakers, associated with the SmartView Connect home monitor, are a perfect example of our objective to improve the management of healthcare by reducing hospital visits while ensuring continuity of monitoring and follow-up.
“These new pacemakers keep patients connected to their clinical team with secured and streamlined communication.”
About the new MicroPort CRM pacemakers
Alizea and Celea utilize the company’s AutoMRI mode to increase safety and quality of life when undergoing MRI examinations. Patients only need to visit their cardiologist once within 10 days before their scan to activate AutoMRI mode. Once programmed, upon entering the MRI field, the pacemaker automatically switches to AutoMRI mode. Following the exam, the devices revert back to initial settings to improve the workflow for patients and medical staff.
MicroPort CRM’s SmartView Connect, a home monitor placed next to the bed, offers ease of use to an elderly patient population. It provides this age group with greater autonomy and involvement in their medical care. The monitor automatically and regularly transmits cardiologist-detailed reports on the functioning of the system. It also sends timely alerts about abnormal rhythms, like AFib, or alerts triggered by patients experiencing symptoms.
“Since launching our first pacemaker more than fifty years ago, MicroPort CRM has continued to develop pioneering cardiac technologies, culminating with this FDA approval for the Alizea and Celea pacemaker systems,” said Aamir Mahmood, VP, Americas. “Our team has worked tirelessly to develop a device that not only improves patient outcomes but also provides convenience and peace of mind for patients and their families. The Alizea and Celea pacemakers, Vega pacing lead, SmartTouch XT programmer, and SmartView Connect remote monitor will make a significant difference in the lives of our patients.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.